Alvotech Stock Hits Day Low of $4.81 Amid Price Pressure

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility on November 3, 2025, with its stock plummeting by 34.25%. The stock reached an intraday low of USD 4.81, reflecting a challenging trading environment. Over the past week, Alvotech's performance has declined by 38.13%, and it has seen a staggering 61.37% drop over the past year, contrasting sharply with the S&P 500's positive performance of 19.89% during the same period.
Key financial metrics indicate underlying issues, including a negative book value and a weak long-term fundamental strength. The company's ability to service its debt is concerning, highlighted by an average EBIT to interest ratio of -7.56. Despite a notable increase in profits by 77% over the past year, the stock has generated a return of -41.06%, suggesting a disconnect between profitability and stock performance.

With a market capitalization of USD 2,463 million, Alvotech's P/E ratio stands at 33.00, while its return on equity is reported at -36.55%. These figures underscore the challenges the company faces in a competitive market landscape.